

RESEARCH ARTICLE

Mixed Th1 and Th2 *Mycobacterium tuberculosis*-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania

Patrizia Amelio¹, Damien Portevin^{2,3}, Klaus Reither^{2,3}, Francis Mhimbira⁴, Maxmillian Mpina⁴, Anneth Tumbo⁴, Beatrice Nickel^{2,3}, Hanspeter Marti^{2,3}, Stefanie Knopp^{2,3}, Song Ding⁵, Adam Penn-Nicholson⁶, Fatoumatta Darboe⁶, Khalid Ohmiti¹, Thomas J. Scriba⁶, Giuseppe Pantaleo^{1,7}, Claudia Daubenberger^{2,3}, Matthieu Perreau¹✉*

1 Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland, **2** Swiss Tropical and Public Health Institute, Basel, Switzerland, **3** University of Basel, Basel, Switzerland, **4** Ifakara Health Institute, Bagamoyo, Tanzania, **5** EuroVacc Foundation, Lausanne, Switzerland, **6** South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa, **7** SVRI, Lausanne, Switzerland

✉ These authors contributed equally to this work.

* Matthieu.Perreau@chuv.ch



OPEN ACCESS

Citation: Amelio P, Portevin D, Reither K, Mhimbira F, Mpina M, Tumbo A, et al. (2017) Mixed Th1 and Th2 *Mycobacterium tuberculosis*-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. *PLoS Negl Trop Dis* 11 (7): e0005817. <https://doi.org/10.1371/journal.pntd.0005817>

Editor: Subash Babu, NIH-TRC-ICER, INDIA

Received: April 26, 2017

Accepted: July 19, 2017

Published: July 31, 2017

Copyright: © 2017 Amelio et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The research leading to these results has received funding from the [European Community's] Seventh Framework Programme (FP7/2007-2013) under EC-GA n° [241642]. This work was also supported by Swiss National Science Foundation Grants 320030_173071 and by the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research

Abstract

Mycobacterium tuberculosis (*Mtb*) and helminth infections elicit antagonistic immune effector functions and are co-endemic in several regions of the world. We therefore hypothesized that helminth infection may influence *Mtb*-specific T-cell immune responses. We evaluated the cytokine profile of *Mtb*-specific T cells in 72 individuals with pulmonary TB disease recruited from two Sub-Saharan regions with high and moderate helminth burden *i.e.* 55 from Tanzania (TZ) and 17 from South Africa (SA), respectively. We showed that *Mtb*-specific CD4 T-cell functional profile of TB patients from Tanzania are primarily composed of polyfunctional Th1 and Th2 cells, associated with increased expression of Gata-3 and reduced expression of T-bet in memory CD4 T cells. In contrast, the cytokine profile of *Mtb*-specific CD4 T cells of TB patients from SA was dominated by single IFN- γ and dual IFN- γ /TNF- α and associated with TB-induced systemic inflammation and elevated serum levels of type I IFNs. Of note, the proportion of patients with *Mtb*-specific CD8 T cells was significantly reduced in *Mtb*/helminth co-infected patients from TZ. It is likely that the underlying helminth infection and possibly genetic and other unknown environmental factors may have caused the induction of mixed Th1/Th2 *Mtb*-specific CD4 T cell responses in patients from TZ. Taken together, these results indicate that the generation of *Mtb*-specific CD4 and CD8 T cell responses may be substantially influenced by environmental factors *in vivo*. These observations may have major impact in the identification of immune biomarkers of disease status and correlates of protection.

Council with funds received from the South African Department of Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Author summary

Mycobacterium tuberculosis (*Mtb*) and helminth infections are co-endemic in several regions of the world and their immune responses may be mutually antagonistic. We therefore hypothesized that helminth infection would impact and potentially shape *Mtb*-specific T-cell responses and systemic inflammation in patients suffering from active pulmonary tuberculosis (TB) enrolled from two helminth endemic regions *i.e.* Tanzania (TZ) and South Africa (SA). In this study, we demonstrate for the first time that TB patients from SA and TZ harbor distinct immune responses to *Mtb* antigens. Indeed, we showed that *Mtb*-specific CD4 T-cell responses of TB patients from TZ were composed by a mixed T helper type 1 (Th1) and Th2 responses. In contrast, the cytokine profile of *Mtb*-specific CD4 T cells of TB patients from SA was dominated by Th1 cells and associated with TB-induced systemic inflammation and elevated serum levels of type I IFN. Taken together, these data indicate that *Mtb*-specific T-cell responses are diverse in human populations and can be strongly influenced by host and pathogen genetic background, co-infections and yet unknown environmental factors. Identification of correlates of risk and protection from TB disease will help in the rational development of protective T-cell based vaccines against TB, early monitoring TB treatment outcomes and focused follow up of high risk populations.

Introduction

Helminth infections are endemic in many African countries with different prevalence depending on the geographic region helminth species and age of population [1]. Soil transmitted helminth infections are among the most common infections, transmitted *via* soil contaminated by eggs excreted from human faeces [2]. Of note, helminth infections are co-endemic in many geographic areas endemic for *Mycobacterium tuberculosis* (*Mtb*), HIV-1 and *Plasmodium falciparum*. Therefore, co-infections of helminths with *Mtb*, HIV-1 and/or *Plasmodium falciparum* occur in a large proportion of the subjects [3].

Mycobacterium tuberculosis (*Mtb*) is a facultative intracellular organism, obligate aerobe, infecting primarily lungs *via* the aerogenic route [4]. It has been recently estimated that 1.7 billion people are infected with *Mtb* among which 5–15% will develop tuberculosis disease (TB) [5]. To date, the only vaccine available to prevent TB disease consist of an attenuate strain of *M. bovis*, the Bacillus of Calmette et Guérin (BCG). While BCG immunization protects from life-threatening disseminated forms of TB disease in children, its efficacy in adults is inconsistent [6]. The protective components of *Mtb*-specific immunity are partially defined. Several studies have underscored the essential role of IL-12/IFN- γ axis in the protection against *Mtb* infection [7–10]. In addition, an efficient CD4 T-cell response probably associated with type 1 cytokine secretion is associated with the control of *Mtb* infection, since a severe reduction in the CD4 T cell number during HIV infection or the suppression of their function following anti-TNF- α therapy are associated with increased risk of TB reactivation [11, 12].

The current paradigm of human cellular immunity indicates that functionally-distinct CD4 T-cell populations are specifically involved against a variety of pathogens depending on their size and their intra- or extra-cellular localization. In this model, type 1 helper CD4 T cells (Th1 cells) intervene against viruses and intracellular pathogens, Th2 cells against parasites such as worms and Th17 cells against extracellular pathogens [13, 14] including bacteria and fungi [14, 15]. Consistent with this paradigm, the protective *Mtb*-specific T-cell response is usually ascribed to typical Th1 response with CD4 T cells producing cytokines such as IFN- γ or TNF-

α that contribute to the recruitment of monocytes and granulocytes and activate the anti-microbial activity of macrophages [16, 17]. By contrast, helminth infections induce IL-4/IL-5 and IL-13 producing CD4 T cells and regulatory T cells [18–21] associated with the alternative activation of macrophages for repair of tissues injured upon migration of worms across different body compartments [1]. With regard to the generation of the functionally distinct T helper CD4 T cell populations, the pioneering studies from Romagnani and others [22, 23], clearly demonstrated the critical importance of the cytokine environment, rather than the specific antigen in the development of distinct T helper antigen-specific CD4 T cells [24, 25]. In this regard, the presence of an IL-4 cytokine background favored the development of Th2 specific to pathogens that usually induce the classical Th1 responses [23, 26].

Multiple studies performed in *Mtb*/helminth co-infected individuals have focused on the impact of helminth infection on 1) TB diagnosis [27–35], 2) reactivation of TB from latently infected individuals (LTBI) [36, 37] and 3) BCG vaccine immunogenicity [38–40]. In addition, it was recently shown that helminth infection may interfere and/or influence innate [41], cellular [42–44] and humoral [45] immune responses to *Mtb*. However limited information is available on the cytokine profile of *Mtb*-specific T-cell immune responses in subjects with *Mtb*/helminth co-infection.

In the present study, we investigated the cytokine profile of *Mtb*-specific immune response in patients with clinically active TB from two countries *i.e.* Tanzania (TZ) and South Africa (SA) in the presence or absence of active helminth infections. We provide evidence that the functional profile of *Mtb*-specific CD4 T cells of TB patients from TZ was characterized by a mixed Th1/Th2 cytokine profile, while that from SA was associated with a typical single IFN- γ and dual IFN- γ /TNF- α Th1 profile.

These results demonstrate that distinct functional profiles of CD4 T-cell responses can be directed against the same pathogen, *i.e.* *Mtb*, in human populations from different geographic areas. *Ad hoc* designed studies will be needed to define the factors driving the distinct functional profiles as well as to determine whether the distinct functional profiles are associated with variation of the TB pathology and/or response to drug therapy.

Results

The aims of the present study were i) to delineate *Mtb*-specific T-cell responses in patients with pulmonary tuberculosis (TB) and helminth co-infection from two Sub-Saharan countries, *e.g.* Tanzania (TZ) and South Africa (SA) and ii) to determine the influence of ongoing or past helminth infections on *Mtb*-specific T-cells responses. Therefore, we analyzed the cytokine profile and cell lineage T cell transcription factor expression in *Mtb*-specific CD4 T cells and serum cytokine levels in 72 individuals (Table 1). The patients were screened for active helminth infections and/or previous exposure to helminths and the cohort stratified into three groups: 1) active TB patients from SA with no sign of active helminth infections, 2) active TB patients from TZ with no sign of active helminth infections and 3) active TB patients co-infected with helminths from TZ (see flow chart, S1 Fig).

Table 1. Demographic and clinical data.

ID	Origin	Number	Mean Age	Gender	Helminth infection	BCG vaccination status
TB SA	South Africa	17	36	3F/12M	11% past exposure	17/17 (100%)
TB TZ	Tanzania	25	29	9F/16M	28% past exposure	25/25 (100%)
<i>Mtb</i> /helminthTZ	Tanzania	30	30	6F/24M	Ongoing	30/30 (100%)

<https://doi.org/10.1371/journal.pntd.0005817.t001>

Mtb-specific CD4 T cells from TB patients from TZ have mixed Th1/Th2 cytokine profile

The functional profiles of *Mtb*-specific CD4 T-cell responses were assessed by intracellular cytokine staining (ICS) according to the gating strategy shown in S2 Fig. In particular, the ability of *Mtb*-specific CD4 T cells to produce IFN- γ , TNF- α , IL-2, IL-4, IL-5 and/or IL-13 in response to ESAT-6 and CFP-10 peptide pools stimulation was assessed by multi-parametric flow cytometry in 25 TB patients and 30 *Mtb*/helminth co-infected patients from TZ and compared to 17 TB patients from SA. Of note, Th2 cytokines *i.e.* IL-4, IL-5 and IL-13 were all assessed in the same flow cytometry fluorescence channel, which allowed the assessment of total Th2 cytokine production but prevented direct identification of individual IL-4, IL-5 or IL-13 *Mtb*-specific CD4 T-cell responses. Cytokine profiles of *Mtb*-specific CD4 T cells from three representative TB patients from SA (#08) and TZ (TB (#60062) and *Mtb*/helminth co-infected patient (#60031) are shown in Fig 1A. We first compared the frequencies of cytokine-producing *Mtb*-specific memory CD4 T cells from TB patients from SA *versus* TB patients from TZ (Fig 1B). The cumulative data showed a significantly higher IL-2⁺ and IL-4/IL-5/IL-13⁺ *Mtb*-specific memory CD4 T-cell frequencies in TB patients from TZ compared with TB patients from SA ($P < 0.05$), while the frequencies of IFN- γ and TNF- α producing *Mtb*-specific memory CD4 T cells were not significantly different between TB patients from TZ and from SA ($P > 0.05$; Fig 1B). Interestingly, no significant differences were observed for Th1 and Th2 cytokine producing CD4 T cells between TB patients from TZ with and without ongoing helminth co-infections ($P > 0.05$) (Fig 1B).

We next analyzed the cytokine profile of *Mtb*-specific memory CD4 T cells of TB patients from SA and TZ (Fig 1C, pie charts). The cytokine profile of *Mtb*-specific memory CD4 T cells of TB patients from SA was significantly different from of TB patients from TZ ($P < 0.05$; Fig 1C, pie charts). Again, no significant differences were observed between TB patients and *Mtb*/helminth co-infected patients from TZ ($P > 0.05$) (Fig 1C, pie charts). In depth analysis showed that *Mtb*-specific CD4 T-cell responses of TB patients from TZ were significantly enriched in polyfunctional IFN- γ ⁺IL-2⁺TNF- α ⁺IL-4/5/13⁺ CD4 T cells (triple IFN- γ /IL-2/TNF- α *Mtb*-specific CD4 T cells) and in IFN- γ ⁺IL-2⁻TNF- α ⁺IL-4/5/13⁺ CD4 T-cell populations (single IL-4/5/13 *Mtb*-specific CD4 T cells) as compared to TB patients from SA (43–42% *versus* 20% for triple IFN- γ /IL-2/TNF- α and 14–16% *versus* 1% for single IL-4/5/13; $P < 0.05$) (Fig 1C). In contrast, *Mtb*-specific CD4 T-cell responses of TB patients from SA were significantly enriched in IFN- γ ⁺IL-2⁻TNF- α ⁺IL-4/5/13⁻ (dual IFN- γ /TNF- α *Mtb*-specific CD4 T cells) and in IFN- γ ⁺IL-2⁻TNF- α ⁻IL-4/5/13⁻ CD4 T-cell populations (single IFN- γ *Mtb*-specific CD4 T cells) as compared to TB patients from TZ (about 45% *versus* 20–18% for dual IFN- γ /TNF- α and 25% *versus* 7–4% for single IFN- γ ⁺; $P < 0.05$) (Fig 1C). No significant differences were observed between the *Mtb*-specific CD4 T-cell cytokine profile of TB patients and *Mtb*/helminth co-infected patients from TZ ($P > 0.05$) (Fig 1C). Of note, *Schistosoma mansoni*-specific CD4 T-cell responses were evaluated on *Mtb*/helminth co-infected individuals from TZ using *S. mansoni* soluble egg antigens (SEA) by polychromatic flow cytometry ($n = 7$). The results obtained showed that SEA-specific CD4 T-cell responses were dominated by single TNF- α and single IL-4/IL-5/IL-13-producing CD4 T cells, while polyfunctional IFN- γ ⁺IL-2⁺TNF- α ⁺ CD4 T cells represented less than 5% of total SEA-specific CD4 T-cell responses confirming previous observations [46, 47] (S3 Fig).

To better estimate the influence of 1) different helminth species, 2) infection caused by more than one helminth (polyparasitism), 3) differences in helminth lung migration capacity and 4) past helminth exposure on the generation of Th2 *Mtb*-specific CD4 T-cells, the proportion of IL-4/5/13-producing *Mtb*-specific CD4 T cells was compared between TB patients




Fig 1. *Mtb*-specific CD4 T cells from TB patients from TZ have mixed Th1/Th2 cytokine profile. (A) Representative flow cytometry profile of *Mtb*-specific CD4 T cells producing IFN- γ , IL-4/5/13, TNF- α and/or IL-2 of one TB patient from SA (#08), one TB patients from TZ

(#60062) and one *Mtb*/helminth co-infected patient from TZ (#60031). Cytokine profiles of CD4 T cells stimulated with SEB (positive control) or left unstimulated (negative control) are also shown. **(B)** Percentage of *Mtb*-specific CD4 T cells producing TNF- α , IFN- γ , IL-2 or IL-4/5/13 of TB patients from SA (n = 17), TB patients from TZ (n = 25) and *Mtb*/helminth co-infected patients from TZ (n = 30). **(C)** Proportion of *Mtb*-specific CD4 T-cell responses producing IFN- γ , IL-4/5/13, TNF- α and/or IL-2 of TB patients from SA (n = 17), TB patients from TZ (n = 25) and *Mtb*/helminth co-infected patients from TZ (n = 30). All the possible combinations of the responses are shown on the x axis and the percentage of the functionally distinct cell populations within the *Mtb*-specific CD4 T-cell populations are shown on the y axis. Responses are grouped and color-coded on the basis of the number of functions. The pie chart summarizes the data, and each slice corresponds to the fraction of *Mtb*-specific CD4 T cell response with a given number of functions within the responding CD4 T-cell population. Bars correspond to the fractions of different functionally distinct CD4 T-cell populations within the total CD4 T cells. Red arcs correspond to IL-4/5/13-producing CD4 T-cell populations. **(D)** Levels of IFN- γ , TNF- α , IL-10, IL-2, IL-4, IL-5, IL-13, IL-17A and IL-17F produced in *Mtb*-stimulated culture supernatants of TB patients from SA (n = 12), TB patients from TZ (n = 21) and *Mtb*/helminth co-infected patients from TZ (n = 29) assessed by luminex assay. TB patients were color coded **(B and D)**; TB patients from SA, blue; TB patients from TZ, red and *Mtb*/helminth co-infected patients, green. Red stars indicate statistical significance. Statistical significance (* = $P < 0.05$) was calculated using one way Anova Kruskal-Wallis test followed by a Mann-Whitney test **(B and D)**. Statistical analyses of the global cytokine profiles (pie charts, **C**) were performed by partial permutation tests using the SPICE software as described [97].

<https://doi.org/10.1371/journal.pntd.0005817.g001>

from TZ with helminth infection caused by one or more helminth species (S4A Fig), or between TB patients from TZ coinfecting with helminth species exhibiting (hookworms and *Strongyloides stercoralis*) or not (*S. mansoni*, *Schistosoma haematobium* and *Wuchereria bancrofti*) lung migration capacity (S4B Fig). Similarly, the proportion of IL-4/5/13-producing *Mtb*-specific CD4 T cells was compared between TB patients from SA or TZ with evidence of past exposure to helminths versus TB patients with no sign of ongoing or past exposure to helminths (S4C and S4D Fig). The cumulative data showed that the proportion of single IL-4/5/13-producing *Mtb*-specific CD4 T cells from active TB cases was not influenced by 1) polyparasitism (including *W. bancrofti*, hookworm, *S. mansoni*, *S. haematobium* or *S. stercoralis*) ($P > 0.05$) (S4A Fig), 2) by helminth infections caused by helminth species exhibiting lung migration capacity, or 3) by past exposure to helminths (S4B and S4C Fig).

To further characterize the cytokine profile of *Mtb*-specific T-cells, multiplex bead array analyses (luminex) were performed on supernatants of ESAT-6/CFP-10 peptide pool (*Mtb*)-stimulated cell cultures. The cumulative data showed that *Mtb*-stimulated cell culture supernatants of TB patients from TZ secreted similar levels of IFN- γ , TNF- α and IL-10 ($P > 0.05$), but significantly higher levels of IL-2, IL-4, IL-5, IL-13, IL-17A and IL-17F than *Mtb*-stimulated cell culture supernatants of TB patients from SA ($P < 0.05$; Fig 1D). However, no significant differences were observed between TB patients and *Mtb*/helminth co-infected patients from TZ ($P > 0.05$; Fig 1D), confirming our flow cytometry analyses. In addition, the levels of Th2 cytokines secreted in *Mtb*-stimulated cell culture supernatants of *Mtb*/helminth patients from TZ was not influenced by individual species of helminth infections, by polyparasitism ($P > 0.05$) (S4E Fig), by helminth species exhibiting lung migration capacity (S4F Fig), or by past exposure to helminths (S4G and S4H Fig).

Taken together, our data indicate that a high proportion of *Mtb*-specific CD4 T cells from Tanzanian TB patients have a mixed Th1/Th2 cytokine profile which is observed either in patients with active helminth infection or in a large proportion of patients with positive helminth serology. In contrast, *Mtb*-specific CD4 T cells from South African TB cases have a classical, previously described Th1 cytokine profile.

Memory CD4 T cells of TB patients from TZ harbor increased Gata-3 and reduced T-bet expression

We then determined whether the development of *Mtb*-specific Th2 CD4 T cells was associated with changes in the expression of Th1 and Th2 cell lineage transcription factors, T-bet and Gata-3 respectively [48, 49].

Representative examples and cumulative data showed that the percentage of memory CD4 T cells expressing Gata-3 was significantly increased in TB and *Mtb*/helminth co-infected patients from TZ (7% and 7.9%, respectively) compared with TB patients from SA (2.4%; $P < 0.05$) (Fig 2A and 2B). In contrast, the percentage of memory CD4 T cells expressing high levels of T-bet (T-bet^{high}) was significantly lower in TB and *Mtb*/helminth patients from TZ (3.6% and 3.2%, respectively) as compared to TB patients from SA (12.3%; $P < 0.05$) (Fig 2A and 2C). However, the frequencies of memory CD4 T cells expressing Gata-3 or T-bet^{high} did not differ between TB patients and *Mtb*/helminth co-infected patients from TZ ($P > 0.05$) (Fig 2B and 2C). In addition, the frequency of memory CD4 T cells expressing Gata-3 of *Mtb*/helminth co-infected patients from TZ was not influenced by the helminth species and by poly-parasitism ($P > 0.05$) (S4I Fig), by helminth species exhibiting lung migration capacity (S4J Fig), or by past exposure to helminths (S4K and S4L Fig). Interestingly, the percentage of T-bet^{high} memory CD4 T cells negatively correlated with the percentage of memory CD4 T cells expressing Gata-3 ($r = -0.6745$; $P < 0.0001$) (S5 Fig) thus supporting previous observations [50].

We then determined whether the expression of T-bet or Gata-3 by memory CD4 T cells was associated with *Mtb*-specific CD4 T-cell cytokine profile of TB patients and *Mtb*/helminth co-infected patients from SA or TZ. To address this issue, we plotted the percentage of *Mtb*-specific CD4 T cells producing IFN- γ or IL-4/5/13 against the percentage memory CD4 T cells expressing T-bet^{high} or Gata-3 from the same patients (Fig 2D and 2E). The cumulative data showed that the percentage of IFN- γ -producing *Mtb*-specific CD4 T cells directly correlated with the percentage of T-bet^{high} memory CD4 T cells ($r = 0.3802$, $P = 0.0085$) (Fig 2D) and the percentage of IL-4/5/13-producing *Mtb*-specific CD4 T cells directly correlated with the percentage of memory CD4 T cells expressing Gata-3 ($r = 0.3782$, $P < 0.0088$) (Fig 2E).

Taken together, these data indicate that TB patients from TZ have a mixed Th1/Th2 cytokine profile associated with increased Gata-3 and reduced T-bet^{high} expression.

Reduced proportion of patients with detectable *Mtb*-specific CD8 T cells in *Mtb*/helminth co-infected patients

Ongoing helminth infections has been shown to interfere with CD8 T cells responses targeting viruses in mouse models [51, 52]. Our group and others has recently shown that *Mtb*-specific CD8 T cells were more frequently detected in patients with TB disease as compared to those with latent *Mtb* infection [53]. Based on this observation, a recent diagnostic test *i.e.* QuantiFERON TB PLUS proposes optimized CD8-TB-specific-peptides stimulation [54, 55]. This prompted us to investigate whether ongoing helminth infections would influence the proportion of TB patients with detectable *Mtb*-specific CD8 T cells. To address this issue, the ability of *Mtb*-specific CD8 T cells to produce IFN- γ , TNF- α , IL-2 and perforin was assessed in 16 TB patients and 23 *Mtb*/helminth co-infected patients from TZ by flow cytometry. As shown in Fig 3A, the proportion of subjects with detectable *Mtb*-specific CD8 T cells was significantly reduced in *Mtb*/helminth co-infected patients from TZ as compared to TB patients from TZ (43.7% versus 80%, respectively; $P < 0.05$; Fig 3A). The frequency of cytokine- and perforin-producing *Mtb*-specific CD8 T cells and the functional profile of *Mtb*-specific CD8 T-cell responses did not differ significantly between TB and *Mtb*/helminth co-infected patients from TZ with detectable *Mtb*-specific CD8 T cells (Fig 3C) and the predominant CD8 T-cell population was IFN- γ ⁺IL-2⁻TNF- α ⁺Perforin⁻ (Fig 3C).

In summary, these data indicate that ongoing helminth infection reduced the proportion of TB cases with detectable *Mtb*-specific CD8 T cells.




Fig 2. Memory CD4 T cells of TB patients from TZ harbor increased Gata-3 and reduced T-bet expression. (A) Representative flow cytometry profile of memory (CD45RA⁻) CD4 T cells (red dots) isolated from one TB patient from SA (#03), one TB patient (#60037) and one *Mtb*/helminth co-infected patient (#60057) from TZ expressing Gata-3 and/or T-bet. Gates were set using naïve (CD45RA⁺) CD4 T cells and CD8 T cells from each individual. Gata-3 and T-bet expression of individual CD8 T-cell are also shown (black dots). Percentage of memory (CD45RA⁻) CD4 T cells isolated from TB patients from SA (n = 12), TB patients (n = 14) and *Mtb*/helminth co-infected patients (n = 13) from TZ expressing Gata-3 (B) or T-bet^{high} (C). (D) Correlation between the percentage of IFN- γ -producing *Mtb*-specific CD4 T cells and the percentage of memory CD4 T cells expressing T-bet^{high} of TB patients from SA (n = 12), TB (n = 14) and *Mtb*/helminth co-infected patients from TZ (n = 13). (E) Correlation between the percentage of IL-4/IL-5/IL-13-producing *Mtb*-specific CD4 T cells and the percentage of memory CD4 T cells expressing Gata-3 of TB patients from SA (n = 12), TB (n = 14) and *Mtb*/helminth co-infected patients from TZ (n = 13). TB patients were color coded (B-E); TB patients from SA, blue; TB patients from TZ, red and *Mtb*/helminth co-infected patients, green. Red stars indicate statistical significance. Statistical significance (* = P<0.05) was calculated using one way Anova Kruskal-Wallis test followed by a Mann-Whitney test (B and C) or Spearman rank test for correlation (D and E).

<https://doi.org/10.1371/journal.pntd.0005817.g002>




Fig 3. Reduced proportion of patients with detectable *Mtb*-specific CD8 T cells in *Mtb*/helminth co-infected patients. (A) Proportion of TB patients with detectable *Mtb*-specific CD8 T cells of TB and *Mtb*/helminth patients from TZ (n = 12 and 7, respectively). (B) Percentage of *Mtb*-specific CD8 T-cell responses producing TNF- α , IFN- γ , IL-2 and/or perforin of TB patients (n = 12) and *Mtb*/helminth patients (n = 7) from TZ. TB patients were color coded; TB patients from TZ, red and *Mtb*/helminth co-infected patients, green. (C) Functional profile of *Mtb*-specific CD8 T cells of TB patients and *Mtb*/helminth co-infected patients from TZ. Red and green circles represent the proportion of *Mtb*-specific CD8 T cells producing TNF- α , IFN- γ , IL-2 and/or perforin of TB and *Mtb*/helminth patients from TZ, respectively (C). Red arcs identify perforin producing cell populations (C). Red stars indicate statistical significance (* = $P < 0.05$). Statistical significance ($P < 0.05$) was calculated using Chi square test (A) and Mann-Whitney test (B). Statistical analyses of the global cytokine profiles (pie charts, C) were performed by partial permutation tests using the SPICE software as described [97].

<https://doi.org/10.1371/journal.pntd.0005817.g003>

Differences in systemic inflammation markers in patients from TZ and SA

One of the objectives of the present study was to determine whether ongoing helminth infection may influence the levels of systemic inflammation markers. In order to address this issue, we first assessed the serum levels of IL-1 α , IL-6, TNF- α , IL-10, IL-12p70, IFN- α 2, IFN- β , IFN- ω , IFN- γ , IL-23 and CRP of TB patients from TZ and SA by multiplex bead array analyses (Fig 4). The cumulative data indicated that the serum levels of IL-1 α , TNF- α , IL-12p70, IFN- α 2, IFN- β , IFN- ω , IL-23 and CRP were significantly increased in TB patients from SA as compared to TB patients from TZ ($P < 0.05$) (Fig 4). However, the levels of IFN- γ , IL-6 and IL-10 were not statistically different between TB patients from SA and TZ ($P > 0.05$; Fig 4). Interestingly,




Fig 4. Differences in systemic inflammation markers in patients from TZ and SA. Serum levels of IL-1 α , IL-6, TNF- α , CRP, IL-12p70, IL-23, IL-10, IFN- α 2, IFN- β , IFN- ω and IFN- γ of TB patients from SA (n = 15), TB and *Mtb*/helminth co-infected patients from TZ (n = 25 and 30, respectively). TB patients were color coded; TB patients from SA, blue; TB patients from TZ, red and *Mtb*/helminth co-infected patients, green. Red stars indicate statistical significance. Statistical significance (* = $P < 0.05$) was calculated using one way Anova Kruskal-Wallis test followed by a Mann-Whitney test.

<https://doi.org/10.1371/journal.pntd.0005817.g004>

ongoing helminth infection did not further influence the serum levels of cytokines and CRP of TB patients from TZ ($P>0.05$) (Fig 4).

Taken together, these data suggest that TB patients from SA and TZ showed differences in serum cytokine profile. In comparison to Tanzanian TB cases, South African patients showed a more pronounced pro-inflammatory serum cytokine profile associated with high levels of type I IFNs.

Th1 cytokine profiles are associated with elevated systemic inflammation markers

To better identify the immunological parameters associated with *Mtb*-specific immune signature in TB patients and the influence of ongoing helminth infection, a principal component analysis (PCA) was performed. The results indicated that the *Mtb*-specific immune profile of TB and *Mtb*/helminth co-infected patients from TZ clustered away from that of TB patients from SA with a percentage of discrimination reaching about 70% (Fig 5A and 5B). In depth analysis revealed that the differentially expressed immune parameters contributing the most to discriminate *Mtb*-specific immune response of TB patients from TZ and SA were the percentages of CD4 T cells expressing Gata-3 and T-bet^{high}, the proportion of polyfunctional TNF- α /IFN- γ /IL-2, dual TNF- α /IFN- γ and single IFN- γ *Mtb*-specific CD4 T cells among total *Mtb*-specific CD4 T-cell responses, levels of IL-5 in *Mtb*-stimulated culture supernatants and IFN- β serum levels (Fig 5A and 5B and Table 2). Again, this analysis did not allow discriminating *Mtb*-specific immune response of TB and *Mtb*/helminth patients from TZ (Fig 5A and 5B).

We next performed multiparametric statistical analysis to investigate the potential associations between the four major represented *Mtb*-specific CD4 T-cell populations *i.e.* triple IFN- γ /IL-2/TNF- α , dual IFN- γ /TNF- α , single IFN- γ and single IL-4/5/13 *Mtb*-specific CD4 T cells, the levels of cytokine detected in *Mtb*-stimulated culture supernatants, *i.e.* IL-2, IL-4, IL-5 and IL-13, the percentages of memory CD4 T cells expressing Gata-3 or T-bet^{high}, and the serum levels of IL-1 α , TNF- α , IL-12p70, IFN- β and IL-23 in TB patients from SA and TZ (Fig 5C). The combined data indicated that IFN- β serum concentrations positively correlated with i) T-bet^{high} memory CD4 T cells, ii) higher proportion of *Mtb*-specific Th1 cells (single IFN- γ and dual IFN- γ /TNF- α), iii) higher serum levels of pro-inflammatory cytokines (IL-1 α and TNF- α), IL-12p70 and IL-23 and negatively correlated with a) Gata-3 expression on memory CD4 T cells, b) higher proportion of polyfunctional *Mtb*-specific CD4 T cells and c) type 2 cytokine secretion (IL-5 and IL-13) ($P<0.05$) (Fig 5C).

Taken together, the data indicate that the serum cytokine profile and the *Mtb*-specific immune signatures of TB patients from SA and TZ are significantly different and that Th1 cytokine profiles are positively associated with TB-induced systemic inflammation and higher serum levels of type I IFNs.

Ongoing helminth infection is not associated with reduced anti-mycobacterial treatment outcome

We then assessed the influence of ongoing helminth infection on TB drug treatment efficiency in the Tanzanian cohort. To address this issue, we first assessed the presence of *Mtb* in the sputum of treated individuals based on sputum smear microscopy. The cumulative data showed a significant reduction in the proportion of patients with detectable *Mtb* in the sputum following 60 days of drug treatment ($P<0.05$; Fig 6A). The presence of an ongoing helminth infection did not influence the effect of anti-mycobacterial drug treatment in relation to sputum detectable *Mtb* ($P>0.05$) (Fig 6A), suggesting that ongoing helminth infection was not associated with reduced anti-mycobacterial treatment efficiency.




Fig 5. Th1 cytokine profiles are associated with elevated systemic inflammation markers. Principal component analysis (PCA) of *Mtb*-specific immunity determined in TB patients from SA (n = 15), TB and *Mtb*/helminth co-infected patients from TZ (n = 25 and 30, respectively). Blue, red and green symbols represent TB patients from SA, TB patients from TZ, and *Mtb*/helminth co-infected patients, respectively. Blue, red and green ellipses represent clusters formed by 70% of TB patients from SA, TB patients and *Mtb*/helminth co-infected patients from TZ, respectively. Blue arrows represent the differentially expressed immune parameters that significantly contributed ($P < 0.05$) to discriminate *Mtb*-specific immune signatures (**A** and **B**). (**C**) Correlogram of imputed Spearman-Rank-Correlation between the proportion of triple IFN- γ /TNF- α /IL-2, dual IFN- γ /TNF- α , single IFN- γ and single IL-4/5/13 *Mtb*-specific CD4 T cells among total *Mtb*-specific CD4 T-cell responses, levels of IL-2, IL-4, IL-5 and IL-13 detected in *Mtb*-stimulated culture supernatants, percentages of memory CD4 T cells expressing Gata-3 or T-bet^{high}, serum levels of IL-1 α , TNF- α , IL-12p70, IFN- β and IL-23 determined in TB patients from SA and TZ (n = 70). Statistical significance was calculated using non parametric test. Empty squares correspond to non significant correlations ($P > 0.05$), blue circles indicate direct correlations and red circles indicate inverse correlations ($P < 0.05$). Blue and red circle sizes indicate statistical amplitude of correlation.

<https://doi.org/10.1371/journal.pntd.0005817.g005>

In addition, 60 days of anti-mycobacterial treatment was associated with a significant increase of the body mass index (BMI) and significant decrease of serum levels of CRP and

Table 2. Contribution of the major differentially expressed immune parameters discriminating *Mtb*-specific immune signatures of TB patients from TZ and SA identified by principal component analysis.

Axes	Variance (%)	Immune parameters	Correlation	P value
Dim1	36.6%	T-bet ^{high}	0.827	3.4E-19
Dim1	36.6%	IFN-β	0.767	3.9E-15
Dim1	36.6%	IFN-γ	0.635	2.1E-09
Dim1	36.6%	IFN-γ/TNF-α	0.277	0.018
Dim1	36.6%	IL-5	-0.284	0.018
Dim1	36.6%	IFN-γ/TNF-α/IL2	-0.303	0.010
Dim1	36.6%	Gata-3	-0.800	3.5E-17
Dim2	18%	IFN-γ/TNF-α	0.835	7.5E-20
Dim2	18%	IFN-γ/TNF-α/IL2	0.670	1.2E-10
Dim2	18%	IL-5	-0.302	0.010
Dim3	15%	IL-5	0.838	4.2E-20
Dim3	15%	IFN-γ/TNF-α/IL2	0.483	1.7E-05
Dim3	15%	Gata-3	-0.288	0.014

Abbreviations: T-bet^{high}, percentage of memory CD4 T cells expressing high level of T-bet; IFN-β, serum level of IFN-β; IFN-γ, proportion of single IFN-γ producing *Mtb*-specific CD4 T cells

IFN-γ/TNF-α, proportion of dual IFN-γ/TNF-α producing *Mtb*-specific CD4 T cells; IL-5, level of IL-5 detected in supernatants of *Mtb*-stimulated cell cultures; IFN-γ/TNF-α/IL-2, proportion of polyfunctional IFN-γ/TNF-α/IL-2 producing *Mtb*-specific CD4 T cells; Gata-3, percentage of memory CD4 T cells expressing Gata-3.

<https://doi.org/10.1371/journal.pntd.0005817.t002>

pro-inflammatory cytokines *i.e.* IL-1α, IL-6, and IL-1β ($P < 0.05$; Fig 6B–6D), irrespective of the presence or absence of ongoing helminth infection ($P > 0.05$) (Fig 6B–6D).

We next assessed the impact of TB treatment initiation on *Mtb*-specific T-cell immunity in TB and *Mtb*/helminth patients. The functional profiles of *Mtb*-specific CD4 T-cell responses and the transcription factor expression profiles were assessed using aforementioned experimental strategies. The cumulative data indicated that the initiation of efficient TB treatment did not significantly influence 1) the *Mtb*-specific CD4 T-cell functional profiles ($P > 0.05$) (Fig 6E), 2) the nature and the amount of Th2 cytokines produced *i.e.* IL-4 and/or IL-5 and/or IL-13 ($P > 0.05$) (S6A Fig) and 3) the transcription factor profile of TB and *Mtb*/helminth infected patients from TZ ($P > 0.05$) (S6B Fig). Indeed, two months after TB treatment, the cytokine profile of *Mtb*-specific CD4 T cells was still dominated by polyfunctional IFN-γ/IL-2/TNF-α and Th2 *Mtb*-specific CD4 T cells (Fig 6E).

In summary, two months of TB treatment did not change the functional profile of *Mtb*-specific CD4 T cells. These data provide evidence that TB treatment outcome during this follow up period was not influenced by presence or absence of ongoing helminth infection.

Discussion

Helminth infections have been shown to impact the control of virus replication in mouse models [52, 56] and interfere with vaccine induced immune responses [57, 58]. Since helminths and *Mtb* are co-endemic in several regions of the world, including Tanzania [1], we hypothesized that ongoing helminth infection may influence and potentially modulate the functional profile of *Mtb*-specific T-cell responses. Our hypothesis is founded on the observations that helminths stimulate Th2 type immune responses and previous studies that demonstrated that the cytokine micro-environment may influence, at least *in vitro*, the functional profile of antigen-specific CD4 T cell responses [59, 60].




Fig 6. Influence of ongoing helminth infection on TB treatment efficiency. (A) Proportion of TB patients (n = 20) and *Mtb*/helminth (n = 24) co-infected patients with detectable *Mtb* prior to and following 60 days of TB treatment. Impact of TB treatment initiation on BMI (B), serum levels of CRP (C) and serum levels of IL-1α, IL-6 and IL-1β (D) of TB (n = 20) and *Mtb*/helminth (n = 22) co-infected patients from TZ prior to and following 60 days of TB treatment. Red and green circles represent TB and *Mtb*/helminth co-infected patients from TZ, respectively. (E) Functional profile of *Mtb*-specific CD4 T cells of TB patients (n = 20) and *Mtb*/helminth (n = 24) co-infected patients from TZ prior to and following 60 days of TB treatment. Blue, red, green and orange circles represent the proportion of *Mtb*-specific CD4 T cells producing TNF-α, IFN-γ, IL-2 and/or IL-4/5/13 in untreated TB patients, 60

days treated TB patients, untreated *Mtb*/helminth co-infected patients and 60 days treated *Mtb*/helminth co-infected patients recruited from TZ, respectively (E). TB patients were color coded; untreated TB patients, blue; treated TB patients, red; untreated *Mtb*/helminth co-infected patients, green; treated *Mtb*/helminth co-infected patients, orange. Red arcs identify IL-4/IL-5/IL-13 producing cell populations (E). Red stars indicate statistical significance (* = $P < 0.05$). Statistical significance ($P < 0.05$) was calculated using Chi square test (A), Wilcoxon signed-rank test (B and C) and one way Anova Kruskal-Wallis test followed by a Mann-Whitney test (D). Statistical analyses of the global cytokine profiles (pie charts, E) were performed by partial permutation tests using the SPICE software as described [97].

<https://doi.org/10.1371/journal.pntd.0005817.g006>

In the present study, we provide evidence that a significant proportion of *Mtb*-specific CD4 T cells in patients with active TB disease from TZ have a Th2 cytokine profile as indicated by the production of IL-4/IL-5/IL-13 and expression of the Th2 cell lineage transcription factor Gata-3. *Mtb*-specific CD4 T-cells comprised Th1 and Th2 cells with a polyfunctional cytokine profile, and the increased frequency of Gata-3⁺ memory CD4 T cells was associated with reduced frequency of T-bet^{high+} memory CD4 T cells. Interestingly, *Mtb*-specific CD4 T cells in patients with active TB disease from SA had a typical Th1 profile encompassing single IFN- γ and dual IFN- γ /TNF- α cells. Taken together, these results demonstrate that active TB disease induced the generation of mixed Th1/Th2 *Mtb*-specific CD4 T cells in patients from TZ whereas a typical Th1 *Mtb*-specific CD4 T cell response was generated in patients from SA. Further investigations would be needed to determine whether TB-uninfected individuals from TZ and SA harbor different basic response to TB antigens.

These observations are of high interest since the assessment of *Mtb*-specific CD4 T-cell cytokine profile is consistently proposed to allow the discrimination between active and latent *Mtb* infections [61–64]. Among, these parameters, high proportions of IL-2-producing *Mtb*-specific CD4 T cells (in association with Th1 cytokines *i.e.* IFN- γ and/or TNF- α) are associated with individuals with LTBI and therefore *Mtb* containment, while high proportion of *Mtb*-specific CD4 T cells producing Th1 cytokines in absence of IL-2 is associated with patients suffering from active TB disease [62–65]. Indeed, reduced capacity to produce IL-2 is usually associated with high antigen load, persistent T-cell stimulation, expression of co-inhibitory molecules and differentiation towards effector memory and/or terminally differentiated effector memory [66, 67]. Interestingly, CD4 T cells coexpressing IFN- γ and TNF- α and harboring a phenotype of effector-memory response were associated with active tuberculosis in HIV-uninfected [68, 69] and HIV-infected TB patients [67]. Of note, polyfunctional helminth-specific CD4 T-cell responses were also recently associated to helminth biological activity [47, 70].

As mentioned above, the study hypothesis was that helminth infection might influence the functional profile of *Mtb*-specific CD4 T cells. In this context, about 67% of patients from TZ either had an ongoing active helminth infection or had evidence of previous helminth exposure/infection. However, about 11% of the patients from SA also showed a positive serology for previous helminth exposure/infection with helminth but no sign of generation of *Mtb*-specific Th2 CD4 T cells. Despite this discordance between positive serology for helminth exposure and lack of the generation of *Mtb*-specific Th2 CD4 T cells in patients from SA, we cannot exclude the frequency and/or severity of helminth re-infection/exposure in patients from TZ is higher as when compared to South African patients and therefore responsible for the mixed Th1/Th2 functional profile of *Mtb*-specific CD4 T cells [71, 72]. In addition, we cannot exclude that human or *Mtb* genetic diversity and other yet unknown environmental factors may contribute to the generation of mixed Th1/Th2 functional cytokine profile and/or influence the durability of the Th2 response after parasite infection is cleared [73] in patients from TZ.

Consistent with previous studies [53, 74], about 80% of TB patients from TZ had *Mtb*-specific CD8 T cell responses detected by polychromatic flow cytometry. Interestingly, this proportion was significantly reduced (about two fold) in the presence of ongoing helminth

Materials and methods

Study group, helminth diagnosis and cell isolation

In total, 72 subjects were recruited to participate in this study. No statistical method was used to predetermine sample size. Fifty-five subjects were recruited at the Mwananyamala Hospital, Dar es Salaam, and the TB clinic of Bagamoyo (TZ). TB patients (n = 55) were selected based on sputum smear microscopy confirmed by GeneXpert assay and HIV infection was ruled out by rapid serological test (Alere Determine HIV-1/2 test). The diagnosis of ongoing and/or past helminth infection was based on assays performed on feces (Kato-Katz thick smear, FLOTAC and Baermann assays), urine (urine filtration), whole blood (Immuno-chromatography) and serum (ELISA) samples at date of blood sample collection and the assay used depended on the helminth species and on the site of sample collection. All TB patients from TZ were screened for active soil-transmitted helminths (hookworms, *Ascaris lumbricoides*, *Trichuris trichiura*) and *S. mansoni* infections using the Kato-Katz thick smear and FLOTAC methods performed on one stool sample at date of blood sample collection, for active *S. stercoralis* infection using the Baermann technique and for active *S. haematobium* infection using the urine filtration method. Binax NOW ICT test card were used to detect *W. Bancrofti* antigen on blood sample [93, 94]. In addition, serology for 7 different helminths (*Echinococcus spp*, *Fasciola hepatica*, *Filaria*, *Schistosoma spp*, *S. stercoralis*, *Toxocara spp* and *Trichinella spp*) was performed by ELISA. The serodiagnostic helminth screening ELISA is routinely performed at the diagnostic centre of the Swiss Tropical and Public Health Institute and detects helminth specific IgG. A total of 30 *Mtb*/helminth co-infected patients were recruited. TB patient co-infected with only one helminth species were infected with *S. mansoni* (n = 7), *W. bancrofti* (n = 6), hookworms (n = 2), *S. haematobium* (n = 2) or *S. stercoralis* (n = 2). Eleven TB patients (36%) were co-infected with multiple helminth species. Blood samples were collected prior to and following 60 days of anti-mycobacterial treatment (“fixed dose combination” consisting of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol, (RHZE)) from 20 TB and 24 *Mtb*/helminth co-infected patients recruited in TZ. In addition, seventeen subjects were enrolled at the field site of the South African Tuberculosis Vaccine Initiative in the Boland Overberg region of the Western Cape Province of SA (SA). TB disease was diagnosed by positive sputum Xpert MTB/RIF and HIV infection was ruled out by rapid serological test. PBMCs were collected as part of a cross-sectional study, in HIV-negative participants before commencing treatment for TB. Diagnosis of helminth exposure was performed using ELISA detecting helminth-specific IgG (*Echinococcus spp*, *Fasciola hepatica*, *Filaria*, *Schistosoma spp*, *S. stercoralis*, *Toxocara spp* and *Trichinella spp*).

Ethics statement

All participants were adults and provided written informed consent and the study protocol was approved for TZ by the Ethikkommission beider Basel (EKBB; Basel, Switzerland; reference number 257/08), the Ifakara Health Institute Institutional Review Board and the National Institute for Medical Research (NIMR; Dar es Salaam, United Republic of Tanzania; reference number NIMR/HQ/R.8a/Vol.IX/1098). For SA, the Human Research Ethics Committee of the University of Cape Town granted the study protocol approval.

Antibodies

The following monoclonal antibodies (mAbs) were used in different combinations. CD3-APC-H7 (CloneSK7), CD4-PECF594 or CD4-APC (Clone RPA-T4), CD8-PB (Clone RPA-T8), IFN- γ -AF700 or IFN- γ -APC (Clone B27), TNF- α -PeCy-7 (Clone MAb11), IL-4-PE

(Clone 3010.211), IL-2-PE (Clone MQ1-17H12), Gata-3-PeCy-7 (Clone L50-823), all from Becton Dickinson (BD); CD45RA-BV711 (Clone HI100), IL-2-PerCpCy5.5 (Clone MQ1-17H12), IL-5-PE (Clone TRFK5), IL-13-PE (Clone JES10-5A2), T-bet-PerCpCy5.5 (Clone 4B10) were purchased from BioLegend; CD8-Efluor625NC (Clone RPA-T8) from eBioscience; perforin-FITC (Clone B-D48) from Diaclone.

Antigens

Mtb-derived CFP-10 and ESAT-6 peptide pools are composed of 15-mers overlapping by 11 amino-acids encompassing the entire sequences of the proteins and all peptides were HPLC purified (>90% purity).

Ex vivo assessment of CD4 T-cell cytokine profile by ICS

PBMCs were stimulated overnight in complete media (RPMI (Invitrogen), 10% fetal calf serum (FCS; Invitrogen), 100 µg/ml penicillin, 100 unit/ml streptomycin (BioConcept)) with ESAT-6 and CFP-10 peptide pools (1 µg/ml) or with *Staphylococcus enterotoxin B* (SEB; 250 ng/mL) or unstimulated in the presence of Golgiplug (1 µl/ml; BD) as previously described [95]. At the end of the stimulation period, cells were washed and stained (20 min; 4°C) for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen), washed and stained (20 min; 4°C) with mAbs to CD3, CD4, CD8 and CD45RA. Cells were then permeabilized (30 min; 20°C) (Cytofix/Cytoperm, BD) and stained (20 min; 20°C) with mAbs to TNF-α, IFN-γ, IL-2, IL-4, IL-5 and IL-13.

Ex vivo assessment of CD8 T-cell cytokine profile by ICS

PBMCs were stimulated overnight in complete media (RPMI (Invitrogen), 10% fetal calf serum (FCS; Invitrogen), 100 µg/ml penicillin, 100 unit/ml streptomycin (BioConcept)) with ESAT-6 and CFP-10 peptide pools (1 µg/ml) or *Staphylococcus enterotoxin B* (SEB; 250 ng/mL) or unstimulated in the presence of Golgiplug (1 µl/ml; BD). At the end of the stimulation period, cells were washed and stained (20 min; 4°C) for dead cells using the Aqua LIVE/DEAD stain kit, then permeabilized (30 min; 20°C) (Cytofix/Cytoperm, BD) and stained (20 min; 20°C) with mAbs to CD3, CD4, CD8, TNF-α, IFN-γ, IL-2 and perforin.

Assessment of T-bet, Gata-3 expression

PBMCs were washed, stained (20 min; 4°C) for dead cells using the Aqua LIVE/DEAD stain kit, then washed and stained (20 min; 4°C) for CD3, CD4, CD8, CD45RA. Cells were then washed, permeabilized (45 min; 4°C) (Foxp3 Fixation/Permeabilization Kit; eBioscience) and stained (20 min; 4°C) with mAbs to T-bet and Gata-3.

Assessment of *Mtb*-stimulated culture supernatant cytokine profile by luminex assay

PBMCs (2×10^5 cells) were stimulated for 24 hours in complete media (RPMI (Invitrogen), 10% fetal calf serum (FCS; Invitrogen), 100 µg/ml penicillin, 100 unit/ml streptomycin (BioConcept)) with ESAT-6 and CFP-10 peptide pools (1 µg/ml) or with *Staphylococcus enterotoxin B* (SEB; 250 ng/mL) or left unstimulated (negative control). At the end of the stimulation period, culture supernatants were collected and levels of TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-13, IL-10, IL-17A and IL-17F were assessed cells by luminex assay (ProcartaPlex Mix&Match Human plex, eBioscience).

Assessment of serum cytokine profile

Serum levels of IL-1 α , IL-6, TNF- α , IL-12p70, IL-23, IL-10, IFN- α 2, IFN- β , IFN- ω and IFN- γ was assessed by luminex assay (ProcartaPlex Mix&Match Human plex, eBioscience) and CRP was assessed by nephelometry (CardioPhaseCRP, Siemens Healthcare Diagnostics Products GmbH) as previously described [96].

Flow cytometry analyses

Cells were fixed with CellFix (BD), acquired on an LSRII SORP (4 lasers: 405, 488, 532 and 633 nm) and analyzed using FlowJo (version 9.7.7) (Tree star Inc, Ashland, OR, USA). Frequencies of cytokine-producing *Mtb*-specific T cells and cytokine profile of *Mtb*-specific T-cell responses were analyzed using SPICE software (version 5.34) following background subtraction. When required, analysis and presentation of distributions was performed using SPICE, downloaded from <<http://exon.niaid.nih.gov/spice>> [97].

Statistical analyses

Statistical significance (*P* values) was obtained either using two-tailed Chi-square analysis for comparison of positive proportions or using one-way ANOVA (Kruskal-Wallis test) followed by Mann-Whitney test or Wilcoxon Matched-pairs two-tailed Signed Rank test for multiple comparisons or Spearman rank test for correlations using GraphPad Prism version 7 (San Diego, CA). Statistical analyses of global cytokine profiles (pie charts) were performed by partial permutation tests using the SPICE software as described [97]. Principal component analysis (PCA) was performed using the R “stats” package. To normalize data distribution, the values of each parameter were first log transformed. Data were then filtered using Lasso method [98].

Supporting information

S1 Fig. Flow chart of the enrolled patients.

(PDF)

S2 Fig. Gating strategy used to assess CD4 T-cell cytokine profile.

(PDF)

S3 Fig. *S. mansoni* soluble egg antigen-specific CD4 T cells from TB/*S. mansoni* co-infected patients from TZ.

Proportion of SEA-specific CD4 T-cell responses producing IFN- γ , IL-4/5/13, TNF- α and/or IL-2 of TB patients from TZ (n = 7). All the possible combinations of the responses are shown on the x axis and the percentage of the functionally distinct cell populations within the SEA-specific CD4 T-cell populations are shown on the y axis. Responses are grouped and color-coded on the basis of the number of functions. The pie chart summarizes the data, and each slice corresponds to the fraction of SEA-specific CD4 T cell response with a given number of functions within the responding CD4 T-cell population. Bars correspond to the fractions of different functionally distinct CD4 T-cell populations within the total CD4 T cells. Red arcs correspond to IL-4/5/13-producing CD4 T-cell populations.

(PDF)

S4 Fig. Influence of the helminth species, polyparasitism, helminth species harbouring lung migration capacity and past helminth exposure on the proportion of *Mtb*-specific CD4 T cells producing Th2 cytokines, on the level of Th2 cytokines secreted and on the percentage of CD4 T cells expressing Gata-3. (A) Proportion of *Mtb*-specific CD4 T cells producing IL-4/5/13 among total *Mtb*-specific CD4 T-cell responses assessed in TB patients

from TZ infected with one helminth (n = 19) as compared to TB patients from TZ infected with more than one helminth (n = 11) or (B) between TB patients from TZ infected with helminth species harbouring (hookworm and *S. stercoralis*) or not (*S. mansoni*, *S. haematobium* and *W. bancrofti*) lung migration capacity. (C) Proportion of *Mtb*-specific CD4 T cells producing IL-4/5/13 among total *Mtb*-specific CD4 T-cell responses assessed in TB patients from SA with (n = 2) or without past helminth exposure (n = 15). (D) Proportion of *Mtb*-specific CD4 T cells producing IL-4/5/13 among total *Mtb*-specific CD4 T-cell responses assessed in TB patients from TZ without ongoing helminth infection but with (n = 7) or without past helminth exposure (n = 18). (E) Levels of IL-4, IL-5 and IL-13 secreted in *Mtb*-stimulated culture supernatants in TB patients from TZ infected with one helminth (n = 19) and TB patients from TZ infected with more than one helminth (n = 10) or (F) between TB patients from TZ infected with helminth species harbouring or not lung migration capacity. (G) Levels of IL-4, IL-5 and IL-13 secreted in *Mtb*-stimulated culture supernatants in TB patients from SA with (n = 2) or without past helminth exposure (n = 10). (H) Levels of IL-4, IL-5 and IL-13 secreted in *Mtb*-stimulated culture supernatants in TB patients from TZ without ongoing helminth infection but with (n = 6) or without past helminth exposure (n = 15). (I) Percentage of memory CD4 T cells (CD45RA⁺) expressing Gata-3 of TB patients from TZ infected with one helminth (n = 8) and TB patients from TZ infected with more than one helminth (n = 5) or (J) between TB patients from TZ infected with helminth species harbouring or not lung migration capacity. (K) Percentage of memory CD4 T cells (CD45RA⁺) expressing Gata-3 of TB patients from SA with (n = 2) or without past helminth exposure (n = 10). (L) Percentage of memory CD4 T cells (CD45RA⁺) expressing Gata-3 of TB patients from TZ without ongoing helminth infection but with (n = 6) or without past helminth exposure (n = 8). Helminth species were color coded (A, E and I); *W. bancrofti*, orange; hookworms, green; *S. mansoni*, red; *S. haematobium*, yellow; *S. stercoralis*, violet, and patients infected with more than one helminth species in light blue. Statistical significance ($P < 0.05$) was calculated by Mann-Whitney test. (PDF)

S5 Fig. The percentage of memory CD4 T cells expressing T-bet^{high} inversely correlates with the percentage of memory CD4 T cells expressing Gata-3. (A) Correlation between the percentage of memory CD4 T cell expressing Tbet^{high} and the percentage of memory CD4 T cell expressing Gata-3 in TB patients from SA (n = 12), TB patient (n = 14) and *Mtb*/helminth co-infected patients (n = 13) from TZ. TB patients were color coded; TB patients from SA, blue; TB patients from TZ, red and *Mtb*/helminth co-infected patients, green. Statistical significance ($P < 0.05$) was calculated using Spearman rank test. (PDF)

S6 Fig. Impact of anti-mycobacterial treatment on the Th2 cytokine secretion and on transcription factor expression. (A) Levels of IL-4, IL-5 and IL-13 produced in *Mtb*-stimulated culture supernatants of TB (n = 13) and *Mtb*/helminth co-infected patients from TZ (n = 18) assessed by luminex assay. (B) Percentage of memory (CD45RA⁺) CD4 T cells expressing Gata-3 or T-bet^{high} of TB (n = 11) and TB/helminth co-infected patients (n = 8) from TZ. TB patients were color coded; TB patients, red and *Mtb*/helminth co-infected patients, green. (PDF)

Acknowledgments

We would like to thank the study participants in TZ and SA for their willingness to donate blood samples for these studies. The invaluable work of Julian Rothen and Tobias Schindler in establishing the helminth infection status of the Tanzanian cohort in Bagamoyo is

acknowledged. Isabelle Zenklusen, Philipp Mächler, Federica Klaus and Jerry Hela facilitated clinical data cleaning and entry of the Tanzanian patients.

Author Contributions

Conceptualization: Giuseppe Pantaleo.

Data curation: Khalid Ohmiti, Matthieu Perreau.

Formal analysis: Patrizia Amelio, Matthieu Perreau.

Funding acquisition: Thomas J. Scriba, Giuseppe Pantaleo, Claudia Daubenberger, Matthieu Perreau.

Investigation: Patrizia Amelio, Francis Mhimbira, Maxmillian Mpina, Anneth Tumbo, Beatrice Nickel, Adam Penn-Nicholson, Fatoumatta Darboe, Khalid Ohmiti, Thomas J. Scriba, Matthieu Perreau.

Methodology: Patrizia Amelio, Matthieu Perreau.

Project administration: Song Ding, Giuseppe Pantaleo.

Resources: Hanspeter Marti, Adam Penn-Nicholson, Fatoumatta Darboe, Thomas J. Scriba, Giuseppe Pantaleo, Matthieu Perreau.

Software: Khalid Ohmiti.

Supervision: Damien Portevin, Klaus Reither, Stefanie Knopp, Thomas J. Scriba, Claudia Daubenberger, Matthieu Perreau.

Validation: Matthieu Perreau.

Visualization: Patrizia Amelio, Khalid Ohmiti, Matthieu Perreau.

Writing – original draft: Patrizia Amelio, Matthieu Perreau.

Writing – review & editing: Damien Portevin, Stefanie Knopp, Adam Penn-Nicholson, Fatoumatta Darboe, Thomas J. Scriba, Giuseppe Pantaleo, Claudia Daubenberger.

References

1. Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on infections with microbial pathogens. *Nat Immunol.* 2013; 14(11):1118–26. <https://doi.org/10.1038/ni.2736> PMID: 24145791.
2. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. *Nat Rev Immunol.* 2011; 11(6):375–88. <https://doi.org/10.1038/nri2992> PMID: 21610741.
3. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. *J Clin Invest.* 2008; 118(4):1311–21. doi: [10.1172/JCI34261](https://doi.org/10.1172/JCI34261). PMID: 18382743.
4. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. *Lancet.* 2015. [https://doi.org/10.1016/S0140-6736\(15\)00151-8](https://doi.org/10.1016/S0140-6736(15)00151-8) PMID: 26377143.
5. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. *PLoS Med.* 2016; 13(10):e1002152. <https://doi.org/10.1371/journal.pmed.1002152> PMID: 27780211; PubMed Central PMCID: PMC45079585.
6. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis.* 2014; 58(4):470–80. <https://doi.org/10.1093/cid/cit790> PMID: 24336911.
7. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman SE, Fondaneche MC, Dupuis S, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. *Nature genetics.* 1999; 21(4):370–8. <https://doi.org/10.1038/7701> PMID: 10192386.
8. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. *Science.* 1998; 280(5368):1435–8. PMID: 9603733.

9. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. *Science*. 1998; 280(5368):1432–5. PMID: [9603732](https://pubmed.ncbi.nlm.nih.gov/9603732/).
10. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. *N Engl J Med*. 1996; 335(26):1956–61. <https://doi.org/10.1056/NEJM199612263352604> PMID: [8960475](https://pubmed.ncbi.nlm.nih.gov/8960475/).
11. Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV. *Clin Infect Dis*. 2010; 50 Suppl 3:S215–22. <https://doi.org/10.1086/651494> PMID: [20397951](https://pubmed.ncbi.nlm.nih.gov/20397951/).
12. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med*. 2001; 345(15):1098–104. <https://doi.org/10.1056/NEJMoa011110> PMID: [11596589](https://pubmed.ncbi.nlm.nih.gov/11596589/).
13. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. *Nature*. 1996; 383(6603):787–93. Epub 1996/10/31. <https://doi.org/10.1038/383787a0> PMID: [8893001](https://pubmed.ncbi.nlm.nih.gov/8893001/).
14. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. *Nat Immunol*. 2007; 8(6):639–46. Epub 2007/05/09. <https://doi.org/10.1038/ni1467> PMID: [17486092](https://pubmed.ncbi.nlm.nih.gov/17486092/).
15. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. *J Exp Med*. 2007; 204(8):1849–61. Epub 2007/07/20. <https://doi.org/10.1084/jem.20070663> PMID: [17635957](https://pubmed.ncbi.nlm.nih.gov/17635957/).
16. Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol*. 2001; 19:93–129. Epub 2001/03/13. <https://doi.org/10.1146/annurev.immunol.19.1.93> PMID: [11244032](https://pubmed.ncbi.nlm.nih.gov/11244032/).
17. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. *Nat Rev Immunol*. 2011; 11(5):343–54. <https://doi.org/10.1038/nri2960> PMID: [21475309](https://pubmed.ncbi.nlm.nih.gov/21475309/).
18. Sher A, Fiorentino D, Caspar P, Pearce E, Mosmann T. Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. *J Immunol*. 1991; 147(8):2713–6. PMID: [1680917](https://pubmed.ncbi.nlm.nih.gov/1680917/).
19. Pearce EJ, McKee AS, Sun J, Cervi L. Th2 response polarization during infection with the helminth parasite *Schistosoma mansoni*. *Immunol Rev*. 2004; 201:117–26. <https://doi.org/10.1111/j.0105-2896.2004.00187.x> PMID: [15361236](https://pubmed.ncbi.nlm.nih.gov/15361236/).
20. McKee AS, Pearce EJ. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. *J Immunol*. 2004; 173(2):1224–31. PMID: [15240714](https://pubmed.ncbi.nlm.nih.gov/15240714/).
21. Anthony RM, Rutitzky LI, Urban JF Jr., Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. *Nat Rev Immunol*. 2007; 7(12):975–87. <https://doi.org/10.1038/nri2199> PMID: [18007680](https://pubmed.ncbi.nlm.nih.gov/18007680/); PubMed Central PMCID: [PMC2258092](https://pubmed.ncbi.nlm.nih.gov/PMC2258092/).
22. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. *Int J Clin Lab Res*. 1991; 21(2):152–8. PMID: [1687725](https://pubmed.ncbi.nlm.nih.gov/1687725/).
23. Romagnani S. Regulation of the T cell response. *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*. 2006; 36(11):1357–66. <https://doi.org/10.1111/j.1365-2222.2006.02606.x> PMID: [17083345](https://pubmed.ncbi.nlm.nih.gov/17083345/).
24. Callard RE. Decision-making by the immune response. *Immunol Cell Biol*. 2007; 85(4):300–5. <https://doi.org/10.1038/sj.icb.7100060> PMID: [17471303](https://pubmed.ncbi.nlm.nih.gov/17471303/).
25. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? *Immunology*. 2008; 123(3):326–38. doi: [10.1111/j.1365-2567.2007.02719.x](https://doi.org/10.1111/j.1365-2567.2007.02719.x) PMID: [179834393439](https://pubmed.ncbi.nlm.nih.gov/179834393439/); PubMed Central PMCID: [PMC2433332](https://pubmed.ncbi.nlm.nih.gov/PMC2433332/).
26. Romagnani S. Th1/Th2 cells. *Inflamm Bowel Dis*. 1999; 5(4):285–94. PMID: [10579123](https://pubmed.ncbi.nlm.nih.gov/10579123/).
27. Metenou S, Babu S, Nutman TB. Impact of filarial infections on coincident intracellular pathogens: *Mycobacterium tuberculosis* and *Plasmodium falciparum*. *Curr Opin HIV AIDS*. 2012; 7(3):231–8. <https://doi.org/10.1097/COH.0b013e3283522c3d> PMID: [22418448](https://pubmed.ncbi.nlm.nih.gov/22418448/); PubMed Central PMCID: [PMC3431797](https://pubmed.ncbi.nlm.nih.gov/PMC3431797/).
28. Rougemont A, Boisson-Pontal ME, Pontal PG, Gridel F, Sangare S. Tuberculin skin tests and B.C.G. vaccination in hyperendemic area of onchocerciasis. *Lancet*. 1977; 1(8006):309. PMID: [64835](https://pubmed.ncbi.nlm.nih.gov/64835/).
29. Gebreegziabih D, Desta K, Howe R, Abebe M. Helminth infection increases the probability of indeterminate QuantiFERON gold in tube results in pregnant women. *BioMed research international*. 2014; 2014:364137. <https://doi.org/10.1155/2014/364137> PMID: [24701572](https://pubmed.ncbi.nlm.nih.gov/24701572/); PubMed Central PMCID: [PMC3950403](https://pubmed.ncbi.nlm.nih.gov/PMC3950403/).
30. Thomas TA, Mondal D, Noor Z, Liu L, Alam M, Haque R, et al. Malnutrition and helminth infection affect performance of an interferon gamma-release assay. *Pediatrics*. 2010; 126(6):e1522–9. <https://doi.org/10.1542/peds.2010-0885> PMID: [21059723](https://pubmed.ncbi.nlm.nih.gov/21059723/); PubMed Central PMCID: [PMC3403682](https://pubmed.ncbi.nlm.nih.gov/PMC3403682/).

31. van Soelen N, Mandalakas AM, Kirchner HL, Walzl G, Grewal HM, Jacobsen M, et al. Effect of *Ascaris Lumbricoides* specific IgE on tuberculin skin test responses in children in a high-burden setting: a cross-sectional community-based study. *BMC infectious diseases*. 2012; 12:211. <https://doi.org/10.1186/1471-2334-12-211> PMID: 22966931; PubMed Central PMCID: PMC3482567.
32. Lipner EM, Gopi PG, Subramani R, Kolappan C, Sadacharam K, Kumaran P, et al. Coincident filarial, intestinal helminth, and mycobacterial infection: helminths fail to influence tuberculin reactivity, but BCG influences hookworm prevalence. *The American journal of tropical medicine and hygiene*. 2006; 74(5):841–7. PMID: 16687690.
33. Neto LM, Oliveira Rde V, Totino PR, Sant'Anna FM, Coelho Vde O, Rolla VC, et al. Enteroparasitosis prevalence and parasitism influence in clinical outcomes of tuberculosis patients with or without HIV co-infection in a reference hospital in Rio de Janeiro (2000–2006). *The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases*. 2009; 13(6):427–32. PMID: 20464334.
34. Zevallos K, Vergara KC, Vergara A, Vidal C, Garcia HH, Evans CA. Tuberculin skin-test reactions are unaffected by the severity of hyperendemic intestinal helminth infections and co-infections. *The American journal of tropical medicine and hygiene*. 2010; 83(2):319–25. <https://doi.org/10.4269/ajtmh.2010.10-0073> PMID: 20682875; PubMed Central PMCID: PMC2911178.
35. Van der Zalm MM, van Soelen N, Mandalakas AM, Jacobsen M, Detjen AK, Marx FM, et al. The Effect of Deworming on Tests of Tuberculosis Infection in Children With Recent Tuberculosis Exposure: A Randomized Controlled Trial. *The Pediatric infectious disease journal*. 2016; 35(6):622–7. <https://doi.org/10.1097/INF.0000000000001115> PMID: 26933841.
36. Elias D, Mengistu G, Akuffo H, Britton S. Are intestinal helminths risk factors for developing active tuberculosis? *Tropical medicine & international health: TM & IH*. 2006; 11(4):551–8. <https://doi.org/10.1111/j.1365-3156.2006.01578.x> PMID: 16553939.
37. Brown M, Miiro G, Nkurunziza P, Watera C, Quigley MA, Dunne DW, et al. *Schistosoma mansoni*, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. *The American journal of tropical medicine and hygiene*. 2006; 74(5):819–25. PMID: 16687687.
38. Malhotra I, Mungai P, Wamachi A, Kioko J, Ouma JH, Kazura JW, et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. *J Immunol*. 1999; 162(11):6843–8. PMID: 10352306.
39. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. *Clin Exp Immunol*. 2001; 123(2):219–25. PubMed Central PMCID: PMC1905995. <https://doi.org/10.1046/j.1365-2249.2001.01446.x> PMID: 11207651
40. Elias D, Britton S, Aseffa A, Engers H, Akuffo H. Poor immunogenicity of BCG in helminth infected population is associated with increased *in vitro* TGF- β production. *Vaccine*. 2008; 26(31):3897–902. <https://doi.org/10.1016/j.vaccine.2008.04.083> PMID: 18554755.
41. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. *J Exp Med*. 2011; 208(9):1863–74. <https://doi.org/10.1084/jem.20091473> PMID: 21825018; PubMed Central PMCID: PMC3171086.
42. George PJ, Anuradha R, Kumaran PP, Chandrasekaran V, Nutman TB, Babu S. Modulation of mycobacterial-specific Th1 and Th17 cells in latent tuberculosis by coincident hookworm infection. *J Immunol*. 2013; 190(10):5161–8. <https://doi.org/10.4049/jimmunol.1203311> PMID: 23576678; PubMed Central PMCID: PMC3646958.
43. George PJ, Anuradha R, Kumar NP, Sridhar R, Banurekha VV, Nutman TB, et al. Helminth infections coincident with active pulmonary tuberculosis inhibit mono- and multifunctional CD4+ and CD8+ T cell responses in a process dependent on IL-10. *PLoS Pathog*. 2014; 10(9):e1004375. <https://doi.org/10.1371/journal.ppat.1004375> PMID: 25211342; PubMed Central PMCID: PMC4161445.
44. Anuradha R, Munisankar S, Bhootra Y, Dolla C, Kumaran P, Nutman TB, et al. Anthelmintic Therapy Modifies the Systemic and Mycobacterial Antigen-Stimulated Cytokine Profile in Helminth-Latent Mycobacterium tuberculosis Coinfection. *Infect Immun*. 2017; 85(4). <https://doi.org/10.1128/IAI.00973-16> PMID: 28167672; PubMed Central PMCID: PMC5364310.
45. Anuradha R, Munisankar S, Bhootra Y, Dolla C, Kumaran P, Nutman TB, et al. Modulation of Mycobacterium tuberculosis-specific humoral immune responses is associated with *Strongyloides stercoralis* co-infection. *PLoS Negl Trop Dis*. 2017; 11(5):e0005569. <https://doi.org/10.1371/journal.pntd.0005569> PMID: 28459817; PubMed Central PMCID: PMC5426788.
46. Caldas IR, Campi-Azevedo AC, Oliveira LF, Silveira AM, Oliveira RC, Gazzinelli G. Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. *Acta tropica*. 2008; 108(2–3):109–17. <https://doi.org/10.1016/j.actatropica.2008.05.027> PMID: 18577364.

47. Petrone L, Vanini V, Petruccioli E, Ettorre GM, Schinina V, Busi Rizzi E, et al. Polyfunctional Specific Response to *Echinococcus Granulosus* Associates to the Biological Activity of the Cysts. *PLoS Negl Trop Dis*. 2015; 9(11):e0004209. <https://doi.org/10.1371/journal.pntd.0004209> PMID: 26575186; PubMed Central PMCID: PMC4648505.
48. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. *Science*. 2001; 292(5523):1907–10. <https://doi.org/10.1126/science.1059835> PMID: 11397944.
49. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. *Nature*. 1996; 384(6608):474–8. <https://doi.org/10.1038/384474a0> PMID: 8945476.
50. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, Young RA, et al. The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. *Proc Natl Acad Sci U S A*. 2009; 106(42):17876–81. <https://doi.org/10.1073/pnas.0909357106> PMID: 19805038; PubMed Central PMCID: PMC2764903.
51. Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. *Proc Natl Acad Sci U S A*. 1993; 90(3):948–52. Epub 1993/02/01. PMID: 8094248.
52. Osborne LC, Monticelli LA, Nice TJ, Sutherland TE, Siracusa MC, Hepworth MR, et al. Coinfection. Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. *Science*. 2014; 345(6196):578–82. <https://doi.org/10.1126/science.1256942> PMID: 25082704; PubMed Central PMCID: PMC4548887.
53. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, et al. Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. *Eur J Immunol*. 2013; 43(6):1568–77. <https://doi.org/10.1002/eji.201243262> PMID: 23456989.
54. Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, et al. First independent evaluation of QuantiFERON-TB Plus performance. *Eur Respir J*. 2016; 47(5):1587–90. <https://doi.org/10.1183/13993003.02033-2015> PMID: 26869677.
55. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. *The Journal of infection*. 2016; 73(6):588–97. <https://doi.org/10.1016/j.jinf.2016.09.008> PMID: 27717779.
56. Reese TA, Wakeman BS, Choi HS, Hufford MM, Huang SC, Zhang X, et al. Helminth infection reactivates latent gamma-herpesvirus via cytokine competition at a viral promoter. *Science*. 2014; 345(6196):573–7. <https://doi.org/10.1126/science.1254517> PMID: 24968940; PubMed Central PMCID: PMC4531374.
57. Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. *J Infect Dis*. 2000; 182(4):1199–206. <https://doi.org/10.1086/315837> PMID: 10979918.
58. Nookala S, Srinivasan S, Kaliraj P, Narayanan RB, Nutman TB. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. *Infect Immun*. 2004; 72(5):2598–604. PubMed Central PMCID: PMC387878. <https://doi.org/10.1128/IAI.72.5.2598-2604.2004> PMID: 15102768
59. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). *Annu Rev Immunol*. 2010; 28:445–89. <https://doi.org/10.1146/annurev-immunol-030409-101212> PMID: 20192806; PubMed Central PMCID: PMC3502616.
60. McKinstry KK, Strutt TM, Swain SL. The potential of CD4 T-cell memory. *Immunology*. 2010; 130(1):1–9. <https://doi.org/10.1111/j.1365-2567.2010.03259.x> PMID: 20331470; PubMed Central PMCID: PMC3502616.
61. Marin ND, Paris SC, Rojas M, Garcia LF. Functional profile of CD4+ and CD8+ T cells in latently infected individuals and patients with active TB. *Tuberculosis (Edinb)*. 2013; 93(2):155–66. <https://doi.org/10.1016/j.tube.2012.12.002> PMID: 23332142.
62. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. *Eur J Immunol*. 2010; 40(8):2211–20. <https://doi.org/10.1002/eji.201040455> PMID: 20540114.
63. Sester U, Fousse M, Dirks J, Mack U, Prasse A, Singh M, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. *PLoS One*. 2011; 6(3):e17813. <https://doi.org/10.1371/journal.pone.0017813> PMID: 21423578; PubMed Central PMCID: PMC3058054.
64. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active

- disease. *Nature medicine*. 2011; 17(3):372–6. Epub 2011/02/22. <https://doi.org/10.1038/nm.2299> PMID: 21336285.
65. Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, et al. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. *The Lancet Infectious diseases*. 2014; 14(10):931–8. [https://doi.org/10.1016/S1473-3099\(14\)70884-9](https://doi.org/10.1016/S1473-3099(14)70884-9) PMID: 25185458.
 66. Jayaraman P, Jacques MK, Zhu C, Steblenko KM, Stowell BL, Madi A, et al. TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. *PLoS Pathog*. 2016; 12(3):e1005490. <https://doi.org/10.1371/journal.ppat.1005490> PMID: 26967901; PubMed Central PMCID: PMC4788425.
 67. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. *The Journal of infection*. 2014; 69(6):533–45. <https://doi.org/10.1016/j.jinf.2014.06.009> PMID: 24975174.
 68. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. *Eur J Immunol*. 2009; 39(3):723–9. <https://doi.org/10.1002/eji.200838693> PMID: 19224636.
 69. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, et al. IFN γ /TNF α specific-cells and effector memory phenotype associate with active tuberculosis. *The Journal of infection*. 2013; 66(6):475–86. <https://doi.org/10.1016/j.jinf.2013.02.004> PMID: 23462597.
 70. Gazzinelli-Guimaraes PH, Bonne-Annee S, Fujiwara RT, Santiago HC, Nutman TB. Allergic Sensitization Underlies Hyperreactive Antigen-Specific CD4+ T Cell Responses in Coincident Filarial Infection. *J Immunol*. 2016; 197(7):2772–9. <https://doi.org/10.4049/jimmunol.1600829> PMID: 27566825; PubMed Central PMCID: PMC45026971.
 71. Speich B, Moser W, Ali SM, Ame SM, Albonico M, Hattendorf J, et al. Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole. *Parasit Vectors*. 2016; 9:123. <https://doi.org/10.1186/s13071-016-1406-8> PMID: 26935065; PubMed Central PMCID: PMC4776366.
 72. Karagiannis-Voules DA, Biedermann P, Ekpo UF, Garba A, Langer E, Mathieu E, et al. Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis. *The Lancet Infectious diseases*. 2015; 15(1):74–84. [https://doi.org/10.1016/S1473-3099\(14\)71004-7](https://doi.org/10.1016/S1473-3099(14)71004-7) PMID: 25486852.
 73. Anuradha R, Munisankar S, Dolla C, Kumaran P, Nutman TB, Babu S. Parasite Antigen-Specific Regulation of Th1, Th2, and Th17 Responses in *Strongyloides stercoralis* Infection. *J Immunol*. 2015; 195(5):2241–50. <https://doi.org/10.4049/jimmunol.1500745> PMID: 26202988; PubMed Central PMCID: PMC4546867.
 74. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. *Clin Infect Dis*. 2015; 60(3):432–7. <https://doi.org/10.1093/cid/ciu795> PMID: 25362202; PubMed Central PMCID: PMC4293395.
 75. Herbst S, Schaible UE, Schneider BE. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. *PLoS One*. 2011; 6(5):e19105. <https://doi.org/10.1371/journal.pone.0019105> PMID: 21559306; PubMed Central PMCID: PMC3085516.
 76. Brighenti S, Andersson J. Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection. *Biochemical and biophysical research communications*. 2010; 396(1):50–7. <https://doi.org/10.1016/j.bbrc.2010.02.141> PMID: 20494110.
 77. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. *Proc Natl Acad Sci U S A*. 1998; 95(1):270–5. PMID: 9419365; PubMed Central PMCID: PMC18198.
 78. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. *PLoS Pathog*. 2009; 5(4):e1000392. <https://doi.org/10.1371/journal.ppat.1000392> PMID: 19381260; PubMed Central PMCID: PMC2663842.
 79. Mazzaccaro RJ, Stenger S, Rock KL, Porcelli SA, Brenner MB, Modlin RL, et al. Cytotoxic T lymphocytes in resistance to tuberculosis. *Adv Exp Med Biol*. 1998; 452:85–101. PMID: 9889963.
 80. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. *J Clin Invest*. 2009; 119(5):1167–77. <https://doi.org/10.1172/JCI38482> PMID: 19381021; PubMed Central PMCID: PMC2673881.
 81. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? *PLoS Pathog*. 2012; 8(5):e1002607. <https://doi.org/10.1371/journal.ppat.1002607> PMID: 22589713; PubMed Central PMCID: PMC3349743.

82. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. *Nat Rev Immunol*. 2015; 15(2):87–103. <https://doi.org/10.1038/nri3787> PMID: 25614319.
83. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. *Science*. 2013; 339(6126):1448–53. <https://doi.org/10.1126/science.1233665> PMID: 23449998; PubMed Central PMCID: PMC3653587.
84. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature*. 2010; 466(7309):973–7. <https://doi.org/10.1038/nature09247> PMID: 20725040; PubMed Central PMCID: PMC3492754.
85. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, et al. Hypervirulent *M. tuberculosis* W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. *J Interferon Cytokine Res*. 2005; 25(11):694–701. <https://doi.org/10.1089/jir.2005.25.694> PMID: 16318583.
86. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Trout J, Shanley C, et al. The hypervirulent *Mycobacterium tuberculosis* strain HN878 induces a potent TH1 response followed by rapid down-regulation. *J Immunol*. 2007; 179(1):522–31. PMID: 17579073.
87. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. The Type I IFN response to infection with *Mycobacterium tuberculosis* requires ESX-1-mediated secretion and contributes to pathogenesis. *J Immunol*. 2007; 178(5):3143–52. PMID: 17312162.
88. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. *Nat Rev Immunol*. 2014; 14(1):36–49. <https://doi.org/10.1038/nri3581> PMID: 24362405; PubMed Central PMCID: PMC4084561.
89. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. *Proc Natl Acad Sci U S A*. 2003; 100(26):15818–23. <https://doi.org/10.1073/pnas.2636938100> PMID: 14673093; PubMed Central PMCID: PMC307651.
90. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. *J Immunol*. 2010; 185(2):813–7. <https://doi.org/10.4049/jimmunol.1000469> PMID: 20554961; PubMed Central PMCID: PMC2927323.
91. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. *Immunology*. 2011; 132(4):466–74. <https://doi.org/10.1111/j.1365-2567.2011.03412.x> PMID: 21320124; PubMed Central PMCID: PMC3075500.
92. Wiens KE, Ernst JD. The Mechanism for Type I Interferon Induction by *Mycobacterium tuberculosis* is Bacterial Strain-Dependent. *PLoS Pathog*. 2016; 12(8):e1005809. <https://doi.org/10.1371/journal.ppat.1005809> PMID: 27500737; PubMed Central PMCID: PMC4976988.
93. Knopp S, Salim N, Schindler T, Karagiannis Voules DA, Rothen J, Lweno O, et al. Diagnostic accuracy of Kato-Katz, FLOTAC, Baermann, and PCR methods for the detection of light-intensity hookworm and *Strongyloides stercoralis* infections in Tanzania. *The American journal of tropical medicine and hygiene*. 2014; 90(3):535–45. <https://doi.org/10.4269/ajtmh.13-0268> PMID: 24445211; PubMed Central PMCID: PMC3945701.
94. Chesnais CB, Missamou F, Pion SD, Bopda J, Louya F, Majewski AC, et al. Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen. *The American journal of tropical medicine and hygiene*. 2013; 89(5):916–8. <https://doi.org/10.4269/ajtmh.13-0245> PMID: 24019435; PubMed Central PMCID: PMC3820335.
95. Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, Maillard M, et al. Lack of *Mycobacterium tuberculosis*-specific interleukin-17A-producing CD4+ T cells in active disease. *Eur J Immunol*. 2013; 43(4):939–48. <https://doi.org/10.1002/eji.201243090> PMID: 23436562.
96. Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. *J Exp Med*. 2014; 211(10):2033–45. <https://doi.org/10.1084/jem.20140039> PMID: 25225461; PubMed Central PMCID: PMC4172212.
97. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. *Cytometry A*. 2011; 79(2):167–74. Epub 2011/01/26. <https://doi.org/10.1002/cyto.a.21015> PMID: 21265010; PubMed Central PMCID: PMC3072288.
98. Tibshirani R, Bien J, Friedman J, Hastie T, Simon N, Taylor J, et al. Strong rules for discarding predictors in lasso-type problems. *Journal of the Royal Statistical Society Series B, Statistical methodology*. 2012; 74(2):245–66. <https://doi.org/10.1111/j.1467-9868.2011.01004.x> PMID: 25506256; PubMed Central PMCID: PMC4262615.